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. Toxin A (TcdA) and toxin B (TcdB), two major C. difficile toxins, induce pro-inflammatory cytokines, disrupt tight junctions, cause cellular detachment and impair the intestinal epithelial barrier [2] [3] [4] [5] [6] [7] [8] . However, the vascular effects of toxin exposure have not been well elucidated. Vascular changes, including angiogenesis and dilatation, have been observed in severe chronic colitis in inflammatory bowel disease (IBD) 9, 10 and may contribute to regional inflammation, haemorrhage, fluid secretion and mucosal damage and repair. In IBD patients, angiogenesis has been shown to be an important component of inflammation [11] [12] [13] and a fundamental mechanism of microvascular adaptation to prolonged colitis 14 . However, for acute colitis, such as that caused by CDI, the vascular response and barrier function have not been characterized.
Vascular endothelial growth factor A (VEGF-A), also known as vascular permeability factor, belongs to a family of growth factors that are involved in vasculogenesis, angiogenesis and vasodilation 15 . VEGF-A is upregulated by hypoxia-inducible factor (HIF) signalling, which is involved in the response to hypoxia and promotes neovascularity 16 . VEGF-A induces the expression of endothelial nitric oxide synthase (eNOS), an essential molecule in the mediation of VEGF-A-induced angiogenesis and endothelial function via production of nitric oxide in endothelial cells 17 . VEGF-A production is elevated in IBD patients and in experimental colitis models 11, 18, 19 , but it is unknown whether VEGF-A plays a role in CDI, which causes acute colitis. Our goal in this study was to evaluate VEGF-A production in response to C. difficile toxins in vivo, in vitro and ex vivo in human colonic mucosa and in CDI patients, and to elucidate the role of VEGF-mediated vascular responses in CDI pathogenesis.
Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis results

CDI increases colonic vascular permeability and angiogenesis in mice.
We observed an increase in the visibility of the macroscopic vasculature in both the colon and caecum of CDI mice 36 (not shown) and 48 h postinfection (Fig. 1a) . To determine whether this increased vascular density is associated with altered vascular permeability in CDI mice, we assessed the vascular permeability in the colon and caecum by systemic injection of Evans blue 14 . Vascular permeability to the dye was remarkably increased in both the colon and caecum of CDI compared to control mice (P < 0.0001 for both colon and caecum; Fig. 1b,c) . To assess whether increased vascular permeability is also due to altered angiogenesis, we stained colon and caecum tissues with von Willebrand Factor (vWF) antibody, an established microvascular endothelial marker. A significant increase in angiogenesis was observed 48 h postinfection (P < 0.01; Fig. 1d ,e). These findings indicate that robust vascular responses, including increased vascular permeability and angiogenesis, occur early during CDI.
TcdA and TcdB induce VEGF-A production in human colonocytes through HIF-α, p38-MAPK and MEK1/2 signalling pathways. To address the molecular mechanism of the vascular changes observed in CDI, we performed human angiogenesis and growth factor arrays in NCM460 human colonocytes exposed to TcdA (1.0 µ g ml −1 ). As shown in Fig. 2a , TcdA induced the production of VEGF-A in colonocytes. IL-8 was also induced, consistent with what we and others have previously reported [20] [21] [22] . In contrast, VEGF-C, VEGF-D, TNF-α , TNF-β , IL-1α , IL-1β , IL-17 and FGF-2 were not significantly induced by TcdA (Fig. 2a) . We found that TcdA induced VEGF-A production in NCM460 colonocytes in a dose-dependent manner (Fig. 2b) . TcdB induced VEGF-A production maximally at 0.01 µ g ml −1 (Fig. 2c ). The production of VEGF-A decreased with the addition of 10 µ g ml −1 TcdB, the highest concentration tested, consistent with a loss of cell viability from the marked cytotoxicity of TcdB at this concentration. We next investigated whether the HIF-α , p38-MAPK and MEK/Erk signalling path ways are involved in toxin-induced VEGF-A production by using pathway specific inhibitors that included FM19G11 5 colony-forming units (c.f.u.) of C. difficile VPI10463. The colon and caecum tissue was harvested at 24 and 48 h postinfection. a, Colorectal tissue that was freshly obtained from control and CDI mice demonstrated more visible colonic vasculature. This experiment was repeated independently at least ten times with similar results. b,c, CDI led to an increase in colonic vascular permeability in mice. The vascular permeability was quantified using the Evans blue extravasation method (c). Data are presented as mean ± s.e.m.; ****P < 0.0001, two-tailed t-test; N = 10 biologically independent animals in each group. d,e, Significant increase in colonic vascular staining in CDI mice. Representative images of vWF staining are shown in d. Scale bars, 100 µ m; N = 5 and 6 biologically independent animals for control and CDI groups, respectively. Data are presented as mean ± s.e.m.; **P = 0.0048, two-tailed t-test. ) for 6, 12 and 24 h. IL-1α , P = 0.184; IL-1β , P = 0.096; IL-6, P = 0.094; IL-17, P = 0.074; VEGF-C, P = 0.250; VEGF-D, P = 0.427; TNF-α , P = 0.060; TNF-β , P = 0.184; FGF-2, P = 0.250; VEGF-A, P = 0.0008 and IL-8, P = 0.0019. Data are presented as mean ± s.e.m; N = 3 biologically independent samples for each group. b,c, NCM460 cells were treated with various concentrations of TcdA or TcdB (0.01, 0.1, 1.0 and 10 µ g ml −1 ) for 12 or 24 h. The concentrations of VEGF-A in the media were quantified by ELISA; N = 3 biologically independent samples for each group. b, TcdA induces dose-dependent VEGF-A production in NCM460 colonocytes. P = 0.070, 0.012, 0.019 and 0.003 for TcdA at 0.01, 0.1, 1.0 and 10 µ g ml −1 , respectively, versus control samples. c, TcdB induces significantly increased VEGF-A production at 0.01, 0.1 and 1.0 µ g ml −1 , but not at 10 µ g ml −1 , due to cell cytotoxicity. P = 0.022, 0.007, 0.016 and 0.217 for TcdB at 0.01, 0.1, 1.0 and 10 µ g ml −1 , respectively, versus control samples. d,e, The HIF-α , p38-MAPK and MEK1/2 signalling pathways are all involved in TcdA-and TcdB-induced VEGF-A production. The TcdA-or TcdB-induced production of VEGF-A in NCM460 cells was inhibited by p38-MAPK (SB203580, 10 µ M), HIF-α (FM19G11, 20 µ M) and MEK1/2 (U0126, 10 µ M or PD98059, 20 µ M) inhibitors. d, P = 0.001, 0.005, 0.0002, 0.024 or 0.003 for control, TcdA + U0126, TcdA + SB230580, TcdA + PD98059 and TcdA + FM19G11 groups, respectively, versus TcdA. e, P = 0.016, 0.004, 0.011, 0.034 or 0.001 for control, TcdB + U0126, TcdB + SB230580, TcdB + PD98059 and TcdB + FM19G11 groups, respectively, versus TcdB. Data are presented as mean ± s.e.m.; two-tailed t-tests were used for all statistical analyses; *P < 0.05; **P < 0.01; ***P < 0.001; N = 3 biologically independent samples. These experiments were individually repeated three times; n.s., not significant. (HIF-α inhibitor), PD98059 (MEK1/2 and Erk1/2 inhibitor), SB203580 (p38-MAPK inhibitor) and U0126 (MEK1/2 inhibitor). We found that TcdA-and TcdB-induced VEGF-A secretion were attenuated by each of these four inhibitors in NCM460 cells, which suggests the involvement of the HIF-α and MAPK pathways in toxin-induced VEGF-A production (Fig. 2d,e) . Similar results were also observed in HT29 cells ( Supplementary Fig. 1 ).
VEGF-A production is elevated in CDI mice in vivo and in human colonic mucosa exposed to toxins ex vivo. By examining this phenomenon in vivo, we found that the VEGF-A mRNA ( Supplementary Fig. 2 ) and protein levels were significantly elevated in both the colon and caecum of CDI mice at 48 h postinfection with VPI10463, a clinical strain that produces high quantities of both TcdA and TcdB (colon, P < 0.01; caecum, P < 0.0001; Fig. 3a ).
To determine whether there is a firm link between toxins and VEGF-A upregulation in vivo, mice were infected with wild type (WT) and isogenic toxin mutants of C. difficile strain M7404, as previously described 23 . At 48 h postinfection, compared to uninfected mice, significantly higher VEGF-A production was observed in the colons of mice infected with WT (P = 0.02), TcdA − B + (P = 0.02) and TcdA + B − (P = 0.079) strains but not with the double negative TcdA − B − mutant (Fig. 3b) , thus establishing the link between toxin production and VEGF-A upregulation during infection. Meanwhile, the TcdA − B + strain induced significantly higher VEGF-A levels than the TcdA + B − strain (P = 0.02; Fig. 3b ), which suggests that TcdA and TcdB have differential effects in the mouse model.
We next evaluated whether VEGF-A was upregulated in toxinexposed human colonic mucosa. We found that TcdA induced significantly elevated VEGF-A production in human colonic mucosa at 1.0 μ g ml −1 (P < 0.01; Fig. 3c ). TcdB significantly induced VEGF-A production at concentrations of 1.0 and 10.0 μ g ml −1 (P = 0.01 and P < 0.05 respectively, Fig. 3d ). In comparison, IL-4 cytokine production did not increase significantly with exposure to either TcdA or TcdB at the tested concentrations ( Supplementary Fig. 3 ).
It has been reported that the activity of eNOS increases the microvascular permeability to macromolecules in response to inflammatory agents 24 . We therefore studied eNOS expression by immunohistochemical imaging and mRNA quantification in colorectal tissues from CDI mice. In addition to increased colonic vasodilation in CDI mice (indicated by the yellow arrows in Fig. 3e ), we found that eNOS staining in sub-mucosal vascular endothelia of CDI mice was significantly higher than that in normal mice (P = 0.005; Fig. 3e ). Furthermore, eNOS mRNA expression was significantly elevated in the colonic tissues of CDI mice (P < 0.05; Fig. 3f ).
Toxin-exposed human colonocytes stimulate HIMEC proliferation mediated by the HIF-VEGF axis. To examine the inter action between human intestinal vascular cells and colonocytes in CDI pathogenesis, we tested whether the induction of VEGF-A expression in colonocytes by C. difficile toxins promotes angio genesis in vitro by measuring the vascular tube formation of human intestinal microvascular endothelial cells (HIMECs). In comparison to control naive cells, NCM460 cells exposed to either TcdA or TcdB significantly enhanced HIMEC tube formation (P < 0.0001 each; Fig. 4a ). These results indicate that products secreted from colonocytes after toxin stimulation can subsequently increase angiogenesis in HIMECs.
To better understand the molecular pathway that mediates the interaction between human intestinal vascular cells and colonocytes exposed to toxins, we examined whether HIF signalling is important in this interaction using our stably transfected HIF-1α knockdown and HIF-1α overexpression cells (western blot in Supplementary Fig. 4 ). Compared to parental WT HCT116 cells, the HIF-1α knockdown cells that were pre-exposed to toxins showed significantly reduced stimulation of HIMEC proliferation (P = 0.0065; Fig. 4b ). In contrast, HIF-1α overexpression in colonocytes significantly enhanced the stimulatory effect on the proliferation of HIMECs (P = 0.04; Fig. 4b ), which was attenuated by VEGF-A neutralizing antibody (P = 0.03, Fig. 4b ). These data underline the importance of the HIF-VEGF axis in mediating the response of human colonocytes to toxins, which subsequently stimulated a colonic vascular response in this in vitro model.
In vivo HIF signalling in a CDI mouse model. Having demonstrated that HIF mediates TcdA-and TcdB-induced VEGF-A production in colonocytes and the subsequent stimulation of colonic vascular endothelial cells, we next tested the in vivo contribution of HIF signalling in CDI pathogenesis.
First, we tested whether the stabilization of HIF expression can alter the outcome of CDI. Dimethyloxalylglycine (DMOG) is a cell permeable, competitive inhibitor of prolyl hydroxylase and has been used to stabilize HIF-1α expression 25 . As shown in Fig. 4c , DMOG treatment significantly exacerbated the death rate in CDI mice (P < 0.0001; N = 10), whereas the eNOS inhibitor L-N GNitroarginine methyl ester (L-NAME) significantly protected CDI mice from death (P = 0.04; N = 10). Weight data for both DMOG and L-NAME experiments are shown in Supplementary Fig. 7 .
Second, we wanted to test whether or not we can alter the outcome of CDI disease by knocking out HIF-1α signalling, specifically in colonic epithelial cells, using intestinal epithelium-specific HIF-1α -knockout mice that we have previously described 26 . As shown in Fig. 4d , the CDI-induced mortality of HIF-1α -knockout mice did not differ significantly from that of their littermate controls. Despite multiple repeat attempts with both control and knockout mice, we failed to generate similar mortality rates to our traditional CDI model. This was probably due to the fact that the mice were bred and shipped from a different research facility, and had unknown microbiota resistant to CDI. The HIF-1α -knockout group had no deaths (N = 5), whereas the control group had one death (N = 9; P = 0.45, logrank test; Fig. 4d ). However, the onset of diarrhoea was delayed by three days in HIF-1α -knockout mice compared to littermate controls (P = 0.03, logrank test; Fig. 4d ). Moreover, HIF-1α -knockout mice had significantly lower weight loss (thus reduced severity) in comparison to WT littermate controls (P = 0.008 on Day 5; Fig. 4d ).
VEGFR-2 kinase inhibition reduces vascular permeability and enhances survival in CDI mice. Given that both VEGF-A production and vascular permeability are significantly elevated by CDI (as shown above) and as VEGFR-2 is the main receptor for VEGF-A 27 , we hypothesized that blocking VEGFR-2 kinase activity might reduce vascular permeability and disease severity in CDI. As shown in Fig. 5a , the administration of SU1498, a kinase inhibitor of VEGFR-2, significantly reduced vascular permeability in CDI mice (colon, P = 0.006; caecum, P < 0.0001; Fig. 5a ). SU1498 also significantly enhanced the survival of CDI mice (63% versus 19%; P = 0.001; N = 22 and 21; Fig. 5b ) and significantly attenuated weight loss during CDI (P = 0.04, 0.01 and 0.01 on Days 6, 7 and 8, respectively; Fig. 5b ). No significant differences were observed in the levels of spores shed in faeces or in the cytotoxic titres of the caecum contents ( Supplementary Fig. 5 ).
Anti-VEGF-A antibody treatment attenuates vascular permeability and protects mice from CDI. We next tested the effects of a VEGF-A blocking antibody on permeability and clinical parameters in mice with CDI. We found that anti-VEGF-A significantly reduced vascular permeability in CDI mice compared to its isotype control (colon, P = 0.0007; caecum, P < 0.0001; Fig. 5c ). Consistent with the reduced vascular permeability, treatment with anti-VEGF-A protected mice from weight loss (P < 0.0001) and significantly ) for 24 h. VEGF-A that was released into the conditioned media was measured using Milliplex human cytokine magnetic bead assays. P = 0.302, 0.006, 0.013 or 0.012 for control versus TcdA (0.1 µ g ml ) and TcdB (10 µ g ml ) groups, respectively; two-tailed t-tests. Data are represented as mean ± s.e.m.; N = 13 in TcdA and N = 5 in TcdB experiments. e, Immunohistochemical analysis of eNOS in colonic tissue of normal or CDI mice. The yellow arrows indicate sub-mucosal vascular vessels. Scale bars, 100 μ m. The graph shows the increased expression score of vascular endothelial eNOS in CDI mice in comparison to controls. P = 0.005, two-tailed t-test; N = 8 biological independent animals in each group. f, Relative quantities from RT-PCR of eNOS expression in control and CDI animals. Data values are expressed as mean ± s.e.m.; *P = 0.0228, two-tailed t-test; N = 5 biological independent animals in each group. *P < 0.05; **P < 0.01; ****P < 0.0001; n.s., not significant. Control CDI increased the overall survival in comparison to the isotype control (62.5% versus 10.0%; P = 0.03; Fig. 5d ). Meanwhile, we found no significant difference between the isotype and untreated controls in these experiments (Fig. 5c,d ). Similarly to the VEGFR-2 inhibitor, anti-VEGF-A did not influence the level of C. difficile spores shed in the fecal samples or the cytotoxic titres of the caecum contents ( Supplementary Fig. 5 ). However, eNOS mRNA expression in the colon was significantly reduced in CDI mice treated with anti-VEGF-A (Supplementary Fig. 6 ).
VEGF-A serum levels increase significantly in CDI patients but decrease following treatment.
To further validate what we observed in the experimental animal models, we decided to compare the expression of VEGF-A under physiologic conditions and acute CDI in clinical settings. We measured the levels of VEGF-A and other cytokines in the sera of healthy human controls and compared those with CDI patients using Milliplex human cytokine/ chemokine magnetic bead assays (Fig. 6a) . The levels of VEGF-A in the sera of patients with CDI (986.0 ± 210.2 pg ml −1 ; N = 50) Using the same approach as in a, the relative HIMEC tube formation was compared between all experimental groups. All cell lines responded to toxins in the subsequent HIMEC stimulation. Compared to WT cells, HIF-1α knockdown cells had significantly lower stimulation of HIMEC proliferation (P = 0.0065), whereas HIF-1α overexpression significantly enhanced the effect on HIMEC (P = 0.04), which was attenuated by VEGF-A neutralizing antibody (P = 0.03). Data are presented as mean ± s.e.m.; two-tailed t-tests were used for statistical analysis; N = 20 replicates in each group. KD, knockdown; OE, overexpression. c, The stabilization of HIF-1α expression exacerbated CDI severity and inhibition of eNOS protected against CDI. CDI mice were treated with DMOG (400 mg kg −1 intraperitoneally; Day 1 and Day 2), L-NAME (20 mg kg −1 intraperitoneally; Day 1, 2 and 3) or vehicle (saline; untreated; Day 1, 2 and 3). Treatment with DMOG significantly exacerbated the death rate in CDI mice (P < 0.0001). In contrast, inhibition of eNOS through the in vivo administration of L-NAME significantly protected CDI mice (P = 0.04). N = 10 biological independent animals in each group; the logrank (Mantel-Cox) test was used for survival analysis. d, Knocking out HIF-1α , specifically in intestinal epithelial cells, reduced CDI symptoms in mice. Both HIF-1α -knockout mice and WT littermate controls were challenged with C. difficile using the same protocol as described earlier.
Litters from both groups were more resistant against CDI compared to our other mice experiments. There was no significant difference in the mortality rate (upper panel; P = 0.456, logrank test). The onset of diarrhoea was significantly delayed and the percentage of diarrhoea symptoms was reduced in HIF-1α -knockout mice (middle panel; P = 0.03, logrank test). There was significantly lower weight loss in the HIF-1α -knockout group compared to WT (lower panel; Day 5, P = 0.008; two-tailed t-test). N = 9 and 5 for the littermate control and HIF-1α -knockout groups, respectively. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant.
were markedly increased (P = 0.001) compared to healthy controls (439.9 ± 85.1 pg ml Table 1 ).
We also compared the levels of VEGF-A and cytokines in the plasma of CDI patients with the paired follow-up sera of each patient (Fig. 6b) . The levels of VEGF-A in the follow-up sera of patients (post-treatment) were significantly reduced compared significantly attenuated vascular permeability in the colon (top) and caecum (bottom) of CDI mice. In the colon, P = 0.0002 and 0.006 for CDI versus control and CDI + SU1498 groups, respectively, and in the caecum, P < 0.0001 for both control and CDI + SU1498 groups versus CDI, two-tailed t-tests; N = 8 biological independent animals in each group. The CDI mice were treated with SU1498 (30 mg kg −1 intraperitoneally daily for 3 d). Colonic and caecal vascular permeability was quantified as described earlier. Data are presented as mean ± s.e.m. b, Treatment with SU1498 significantly enhanced the survival of CDI mice in comparison to vehicle control mice (63% versus 19%; P = 0.001, logrank test; N = 22 and 21 biological independent animals; upper panel). Relative body weights were monitored daily and compared using the Mann-Whitney U test. Treatment with SU1498 reduced CDI-associated weight loss as compared to vehicle control mice (P = 0.044, 0.012 and 0.012 at Day 6, 7 and 8, respectively, two-tailed t-tests; N = 22 and 21 biologically independent animals; lower panel). Data are presented as mean ± s.e.m. c, Treatment with anti-VEGF-A significantly attenuated vascular permeability in CDI mice compared to treatment with an isotype control (N = 6 biological independent animals in each group). CDI mice were either untreated or treated with anti-mouse VEGF-A antibody or isotype control administered by intraperitoneal injection at 12 h and 36 h after C. difficile challenge. Colonic and caecal vascular permeability was quantified as described earlier. P = 0.154, untreated versus isotype control, colon; P = 0.0007, isotype control versus antimouse VEGF-A, colon; P = 0.197, untreated versus isotype control, caecum; and P < 0.0001, isotype control versus anti-mouse VEGF-A, caecum; two-tailed t-tests. Data are presented as mean ± s.e.m. d, Anti-VEGF-A antibody treatment protected mice from weight loss (P < 0.0001, two-tailed t-test; data are presented as mean ± s.e.m.) and significantly increased the overall survival relative to isotype controls (62.5% versus 10.0%; P = 0.03, logrank test). N = 8 for the anti-VEGF-A and isotype groups, and N = 10 in the untreated group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., not significant.
with the sera following CDI diagnosis (interval decrease in 73.9% patients; N = 23; P = 0.015), which indicates that VEGF-A levels are associated with CDI disease status.
Discussion
Our results indicate that C. difficile toxin-induced VEGF-A production and vascular permeability contribute substantially to the pathogenesis of CDI. We observed toxin-induced VEGF-A induction in human colonocytes in vitro, in an in vivo CDI mouse model (particularly with isogenic toxin-gene mutants), in human colonic mucosa biopsies, and more importantly, enhanced serum levels of VEGF-A in CDI patients and its correlation with disease status. There is increasing evidence that VEGF-A is an important component of chronic colitis, such as IBD pathogenesis 28, 29 . VEGF-A is elevated in distal colonic tissue in a murine colitis model 18 as well as in the intestinal tissues and sera of patients with Crohn's disease and ulcerative colitis 13, [29] [30] [31] [32] . Prominent vascular changes in the colon have also been observed during clinical CDI 33, 34 . Oedema, hypoxaemia and colonic wall thickening are observed by computed tomography scans and colonoscopies in CDI patients 33 . In addition to the enhanced vascular dilation and permeability observed in the CDI mouse model, we also reported marked increases in blood flow and neutrophilic invasion of the lamina propia in rabbit intestines exposed to purified TcdA 34 . The substantial role of VEGF-A in both CDI and IBD may suggest a common role of VEGF-A in both acute and chronic colonic inflammation of different aetiologies.
VEGF was originally described as an endothelial cell-specific mitogen. However, VEGF and VEGF receptors are also expressed on numerous non-endothelial cells, including tumour cells. In this study, we observed that colonic epithelial cells produced and released VEGF-A in response to C. difficile toxins, indicating that colonocytes may be an important source of colonic VEGF-A, which is more typically thought to arise from vascular endothelial cells. The induction of VEGF-A production appeared to be mediated by Erk/P38-MAPK-and HIF-α -dependent signalling pathways (Fig. 2d,e) . This complements the results of our previous studies and others, which show that the HIF-1α /2α , p38-MAPK and MEK/ Erk signalling pathways are activated by C. difficile toxins 20, 21, 35 . In the study by Hirota et al., the stabilization of HIF-1α with DMOG attenuated toxin-induced injury and inflammation in mouse ileal loops injected with TcdA 35 . In our CDI mouse model, however, we found that stabilization of HIF-1α by DMOG exacerbated CDI symptoms (Fig. 4c) . This inconsistency may derive from the two different models (whole bacterial infection versus toxin ilealloop injection). The knockdown and overexpression of HIF-1α in the HIMEC stimulation assay reported here suggests that HIF signalling in the colonocytes mediates toxin-induced VEGF production, which subsequently stimulates intestinal vascular endothelial cells (Fig. 4b) .
Our finding adds another layer to our understanding of barrier function in colonic infection and inflammation, an area where the epithelial cell barrier has been extensively studied but vascular permeability far less so. The target of VEGF-A is presumably colonic microvascular endothelial cells, as we demonstrated in vitro that colonocytes pre-exposed to toxins subsequently stimulated human intestinal vascular cells. In addition, a more permeable vascular barrier correlated with increased VEGF-A in the CDI mouse model. Therefore, TcdA and TcdB not only directly cause a breach in the epithelial barrier through the disruption of epithelial tight junctions [6] [7] [8] , but also indirectly induce VEGF-A production, which leads to a more permeable vascular intestinal barrier. This in turn could explain the reported systemic dissemination of TcdA and TcdB in CDI animal models and in human toxaemia cases 36, 37 . In addition, the leaky vascular barrier may contribute to the C. difficile toxinmediated transport of systemic antibodies into the gut lumen, as we previously reported 38 . It is conceivable that there might be direct toxic effects on vasculature once toxins disseminate during the late stage of severe CDI, although this was not investigated in the current study.
Notably, alteration of vascular permeability may not be the only role of VEGF-A in CDI pathogenesis. VEGF-A is also an important pro-inflammatory cytokine that facilitates endothelial cell and monocyte/macrophage migration 15 . VEGF itself can induce other pro-inflammatory cytokines such as IL-8 39 . Meanwhile, anti-VEGF antibody significantly reduced the vascular effect induced by toxin-exposed epithelial cells (Fig. 4b) . However, because it did not achieve full reduction to the baseline, it may suggest that other cytokines, such as IL-8, could also contribute to this effect.
The colonic vascular barrier is not well studied in enteric infections. However, our data provide evidence that the breach of colonic vascular barrier induced by bacterial virulence factors contributes to the pathogenesis of enteric infections. Therefore, VEGF-A could serve as a potential target for CDI treatment. This might enable host-directed therapy as an alternative approach to the pathogentargeted therapies used in the treatment of this enteric infection. Avastin (Bevacizumab) is a humanized anti-VEGF-A monoclonal antibody that has been used to treat various cancers and eye diseases 40 . Recently, Mvasi (bevacizumab-awwb), a biosimilar of Avastin, became the first biosimilar to be approved by the FDA for cancer treatment 41 . Our current report suggests that both Avastin and Mvasi may warrant consideration in treating patients with severe, refractory CDI or CDI in patients with IBD, although their potential side effects in those patients should also be considered.
Methods
C. difficile culture and toxin purification. The C. difficile strain VPI10463 (ATCC) stock suspension was inoculated in Difco cooked meat media (BD Diagnostic Systems) for 36 h at 37 °C. TcdA and TcdB were purified as previously described 20, 42, 43 . The WT and isogenic toxin mutants of C. difficile strain M7404 are listed in Supplementary Table 1 and have been described previously   23 .
Cell culture. NCM460, a non-transformed human colonocyte line, was maintained in M3D medium (INCELL Corporation). HT29 and HCT116 human colonic cancer cells (ATCC) were maintained in DMEM. Cells were seeded in 12-well plates, cultured in a 37 °C humidified incubator with 5% CO 2 and grown to 70-100% confluency. Cells were then serum-starved overnight and purified TcdA or TcdB was diluted in culture media and added at the indicated concentrations for varying lengths of time. In cell signalling experiments, NCM460 cells were treated with TcdA (1.0 µ g ml −1 ) or TcdB (1.0 µ g ml −1 ) in the presence or absence of inhibitors specific to p38-MAPK (SB203580; 10 µ M), HIF-1α/2α (FM19G11; 20 µ M), MEK1/2 (U0126; 10 µ M, or PD98059; 20 µ M) for 12 or 24 h. HIMECs were isolated as previously described 44 . Briefly, HIMECs were obtained from normal areas of the intestine of patients admitted for bowel resections. The HIMECs were isolated by enzymatic digestion and subsequently cultured in MCDB131 medium (SigmaAldrich) supplemented with 20% fetal bovine serum (BioWhittaker, Inc.), antibiotics (BioWhittaker), heparin (Sigma-Aldrich) and endothelial cell growth factor (Hybridoma Core Facility). Cultures of HIMECs were maintained at 37 °C in 5% CO 2 . The HIMECs were used between passages 7 and 12. Cell lines were not further authenticated, but were determined to be free of mycoplasma contamination using the PlasmoTest Detection Kit (InvivoGen). HCT116 HIF-1α knockdown and HIF-1α overexpression cell lines were generated and validated as previously described 45, 46 .
Tube formation assay. Cells (NCM460) were treated with TcdA or TcdB at 1.0 µ g ml
. In the HIF-1α experiment in Fig. 4b , HCT116 parental (WT) cells, HIF-1α knockdown and overexpression cells were treated with a mixture of TcdA and TcdB (1.0 µ g ml −1 each). Cell culture media were collected 24 h later, centrifuged at 1,000 g for 5 min (to remove floating cells), ultra-filtered to remove toxins using Amicon ultra centrifugal filters (100KD; EMD Millipore, Inc) and applied to HIMECs (diluted 1:1 with HIMEC culture media); tube formation was assessed 24 h later. Cells were labelled with calcein (Life Technologies) for 30 min according to the manufacturer's instructions and were visualized with a Leica DMI6000 microscope (Leica Microsystems GmbH). Images were captured with an Orca-R2 ER-150 CCD camera (Hamamatsu Photonics K.K.) and processed with Photoshop CS5 version 12 (Adobe Systems Inc.) as previously described 19 . The relative total tube length present in each entire field (pixels pixels −2 ) was measured using ImageJ version 1.46d (NIH). For these histological imaging analyses, investigators were blinded to the group of the animals.
CDI mouse model. The mouse antibiotic-associated CDI model was employed as previously reported 47 . Briefly, 8-week-old female C57BL6 mice (Jackson Laboratory) were used in all experimental groups. Each mouse was administrated an antibiotic mixture of kanamycin (40 mg kg
), gentamicin (3.5 mg kg
), colistin (4.2 mg kg
), metronidazole (21.5 mg kg
) and vancomycin (4.5 mg kg
) in drinking water for 3 d, followed by a single dose of clindamycin (10 mg kg −1 ) intraperitoneally 2 d later, 24 h before challenge with 0.5 × 10 5 c.f.u. C. difficile (strains VPI10463, 3232 or CF2). The weight and survival of the mice were monitored daily. In experiments of mice infected with isogenic mutant strains, the mouse model was based on a modified version of a previously described model 23 . The intestinal epithelium-specific HIF-1α -knockout mice, HIF-1α ΔIE and littermate controls were described as previously reported 26 . All animal experiments were performed in accordance with the guidelines of the IACUC committee of Beth Israel Deaconess Medical Center and the Monash University Animal Ethics Committee (Monash University AEC no. SOBSB/M/2010).
Immunohistochemistry. Mice colorectal tissues were fixed in 4% paraformaldehyde for 4 h, embedded and frozen in Tissue-TeK O.C.T. Compound (SAKURA Finetex) and 5 μ m sections were mounted on slides. Immunohistochemistry was performed using either rabbit polyclonal vWF antibody (BD Pharmingen) or rat anti-mouse eNOS antibody (Thermo Scientific), as reported in earlier work 24, 48 . Images of the stained colorectal tissues were captured using a Zeiss microscope system. The relative density of eNOS staining in sub-mucosal vessels was analysed and standardized using Volocity 3D Image Analysis Software 6.3 (Perkin Elmer, Inc.). Computerized vWF-stained image analysis was performed using the Scion Image Software (Scion Corp.) as previously described 19 .
In vivo administration of SU1498, VEGF-A antibody or DMOG. To inhibit VEGFR-2, mice were treated with daily intraperitoneal injections of 100 μ l SU1498 (30 mg kg −1 in dimethyl sulfoxide, Sigma-Aldrich, Inc.) or dimethyl sulfoxide alone starting on the day of C. difficile gavage and continuing daily for 3 d ; Biolegend, Inc.) 50 at 12 and 36 h following C. difficile challenge. To stabilize HIF-1α prolyl hydroxylase, mice were treated daily with intraperitoneal injections of 100 μ l DMOG (400 mg kg −1 in saline; Cayman Chemical) starting on the day of C. difficile gavage for 2 d.
Cytokine measurement. Mice colorectal tissues were weighed and homogenized in RIPA buffer with a protein kinase inhibitor cocktail (1 g tissue in 10 ml buffer). Total protein was quantified by Bradford assays. Tissue or human sera cytokines (VEGF-A, IL-10, IL-12, IL-17, IL-23, IL-33 and IFNγ ) were measured by ELISA or Multiplex human cytokine/chemokine magnetic bead assays (EMD Millipore, Inc).
Vascular permeability assay.
To evaluate vascular permeability as previously described 51 , we injected Evans blue (30 mg kg −1 in 100 μ l PBS; Sigma Chemical Co.) into the tail vein of mice 36 h after C. difficile challenge. Mice were killed 20 min after Evans blue injection, photographs were taken and colorectal tissues were removed and cut along the sagittal direction; faeces were removed and blotted dry. The Evans blue dye was extracted with 1 ml of formamide overnight at 55 °C and measured spectrophotometrically at 600 nm. Data were expressed as mean ± s.e.m. Comparisons of the amounts of dye extravasation were evaluated using the unpaired t-test.
Quantification of spores from mice faeces. Fecal samples were collected on Day 1-3, 40 mg faeces samples were hydrated with 500 μ l sterile water for 16 h at 4 °C, 500 μ l absolute ethanol was then added and samples were incubated for 60 min at room temperature. Samples were serially diluted and plated onto selective medium supplemented with taurocholate (0.1% w/v), cefoxitin (16 μ g ml
), L-cycloserine (250 μ g ml
) (TCCFA plates). The plates were incubated anaerobically at 37 °C for 48 h, colonies were counted and results expressed as log 10 [c.f.u. per gram of faeces].
Caecum content cytotoxicity assay. Cells (3T3) were seeded in a 96-well plate at a density of 10 5 cells well −1 . The caecum contents from mice were suspended in PBS at a ratio of 1:10, vortexed and centrifuged (14,000 r.p.m., 5 min). The supernatant was filter sterilized, serially diluted in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin, and 100 μ l volumes were added to 3T3 wells. After 24 h of incubation at 37 °C, plates were screened for cell rounding. The cytotoxic titre was defined as the reciprocal of the highest dilution that produced rounding in at least 50% of cells per gram of caecal luminal samples under × 200 magnification.
Ex vivo human colonic mucosal biopsy culture and cytokine measurement.
Normal human colonic mucosa were obtained by forceps biopsy from the distal colon of healthy volunteers undergoing screening colonoscopies according to a protocol approved by the Committee on Clinical Investigation (Institutional Review Board) of Beth Israel Deaconess Medical Center. All human biopsy samples were obtained with informed consent. Biopsies were washed with ice-cold plain medium and immediately transferred to a 24-well plate. Each biopsy well contained 0.5 ml RPMI-1640 with 100 U ml −1 penicillin and 100 µ g ml −1 streptomycin (Life Technologies) that contained TcdA (0.1 or 1.0 μ g ml ). We maintained the cultures in 95% O 2 and 5% CO 2 at 37 °C for 24 h and then harvested the supernatants for VEGF-A and cytokine measurements using Milliplex human cytokine/chemokine magnetic bead assays.
Patient sera. Stored sera from previous prospective cohort studies of the host immune response to nosocomial CDI were examined 52 . These included sera from healthy controls (N = 35), patients with CDI following diagnosis (N = 50) and follow-up CDI patients after treatment (> 5 d; N = 23). C. difficile diarrhoea was defined as diarrhoea not attributed to any other cause and associated with a positive stool test for C. difficile toxin. This study was approved by the Institutional Review Boards of Beth Israel Deaconess Medical Center. Discarded laboratory samples and samples obtained from patients who provided written informed consent were collected. Additional information regarding clinical study design, patient demographics and risk factors for CDI has been published previously 52 .
Statistical analysis.
We performed statistical analysis with the use of GraphPad Prism 6 software program (GraphPad Software). Analyses using the MannWhitney test, two-way ANOVA, t-test and paired t-test were performed as appropriate. Results are expressed as mean ± s.e.m. unless otherwise indicated. Survival data were analysed by Kaplan-Meier survival analysis. P values lower than 0.05 were considered statistically significant. Investigators were blinded to the groups of the animals or human subjects for histological imaging and cytokine analysis, but not for survival experiments and analysis. The animals were randomly allocated to experimental groups. There was no exclusion of data points. 
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